Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...
As GLP-1 therapies reshape obesity care, Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues that ...
Kardigan raised $400M gross by selling 25M shares at $16, with a 3.75M-share greenshoe, and shares jumped up to 31% on debut. Three late-stage programs target high-unmet cardiovascular niches: ...
Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
RayThera contributes multiple undisclosed-mechanism small-molecule immunology candidates positioned for broad applicability across immune-mediated indications, expanding modality diversity beyond ...
A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results